The Pharmacodynamics are good and Xanamem does what it was designed to do. Just haven't proved that reducing cortisol improves cognition yet. It's going to be interesting to see what ACW have found resulting from Phase II trial and additional studies. Let's hope they have some sound evidence to present to the market and Pharma.
Ann: Appendix 4E & Annual Report, page-41
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.98M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.5¢ | 2.3¢ | $146.4K | 5.980M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1293461 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 336163 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |